In times of extreme stress, people fall back on black humor, which explains the joke making the rounds of health care buysiders trying to cope with the relentless selling of biotech and drug stocks.

“Are you hearing anything about a big fund liquidating? This market feels like a big fund is liquidating.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • small cap Biotechs have been shorted mercilessly and subsequently subjected to all kinds of hit pieces.

    Look no further than JP Morgan’s dishonest and lazy hit job on SGMO today.

    Mr. Feuerstein should know a thing or two about shorting a company and then writing misleading hit pieces.

    • That JPM piece on SGMO was awful. Not only was it factually inaccurate, but the analyst apparently flubbed the numbers horribly. Either sloppy, incredibly stupid, or purposefully malignant, hard to decide which. I have no position in SGMO but my sympathies go out to the shareholders on this one.

    • Any different than the mob?

      MICHAEL
      Tom, wait a minute. I’m talking about a cop — that’s mixed up in drugs. I’m talking about ah
      – ah – a dishonest cop — a crooked cop who got mixed up in the rackets and got what was
      coming to him. That’s a terrific story. And we have newspaper people on the payroll, don’t
      we, Tom?
      [Hagen nods in the affirmative]
      And they might like a story like that.

      HAGEN
      They might, they just might…

  • Do you think owning MDGL and VKTX is worth at these prices or expecting more downside – if one dares to own these until 2022-23?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy